Acrux signs second distribution agreement with CSL

By Melissa Trudinger
Tuesday, 30 November, 2004

Acrux (ASX: ACR) has signed a second distribution agreement with CSL (ASX: CSL), giving CSL the rights to distribute Acrux's Fentanyl MDTS treatment for severe pain.

The product, which is undergoing Phase I clinical development, will be distributed by CSL Pharmaceuticals in Australia and New Zealand. Acrux will receive both an upfront payment plus royalties on net sales.

Earlier this year, CSL agreed to distribute Acrux's testosterone MDTS treatment for low testosterone levels and sexual dysfunction in women.

Content from other channels on our network

Breaking the biofilm shield that harbours foodborne pathogens

Second cell-cultured food under assessment by FSANZ

Indigenous food culture and responsible seafood celebrated

Shaking up whey protein manufacturing technique

Danone to acquire Made Group

Deakin University launches metal resources research centre

Dragos introduces OT-native cybersecurity AI

Construction begins on south‍-‍west WA advanced manufacturing hub

Newcastle carbon capture plant opens

Accenture acquires Dragos and increases OT cybersecurity offering

Detoxifying 'super fungi' may recover critical minerals

Training centre opens to improve alloy lifecycle

Water utilities know where AI fits — but can the foundations carry it?

FIFA World Cup to generate 156 tonnes of plastic waste

Collaboration provides NZ's largest smart water meter upgrade

Acrux signs second distribution agreement with CSL

Australia's first cases of H5 avian influenza confirmed

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Content from other channels on our network